Enanta Pharmaceuticals (ENTA) Common Equity (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Common Equity of $116.6 million for Q1 2026, up 24.64% year-on-year from $93.5 million in Q1 2025, and down 7.9% on a QoQ basis from $126.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Common Equity data on file, last reported at $116.6 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 24.64% year-over-year to $116.6 million; the trailing twelve-month figure through Mar 2026 stood at $116.6 million (up 24.64% YoY), and the FY2025 full-year result was $64.7 million, down 49.76% from the prior year.
- Common Equity for Q1 2026 stood at $116.6 million, down from $126.6 million in the prior quarter.
- Across five years, Common Equity topped out at $358.6 million in Q1 2022 and bottomed at $64.7 million in Q3 2025.
- The 5-year median for Common Equity is $166.1 million (2024), against an average of $192.4 million.
- The widest annual swing landed in 2025, when Common Equity tumbled 49.76%; it then increased 24.64% in 2026.
- A 5-year view of Common Equity shows it stood at $300.8 million in 2022, then plunged by 36.22% to $191.9 million in 2023, then plunged by 41.73% to $111.8 million in 2024, then increased by 13.21% to $126.6 million in 2025, then retreated by 7.9% to $116.6 million in 2026.
- The last three Common Equity figures came in at $116.6 million (Q1 2026), $126.6 million (Q4 2025), and $64.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 116.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.59 Mn |
| Dec 31, 2025 | 126.59 Mn |
| Sep 30, 2025 | 64.72 Mn |
| Jun 30, 2025 | 79.28 Mn |
| Mar 31, 2025 | 93.54 Mn |
| Dec 31, 2024 | 111.82 Mn |
| Sep 30, 2024 | 128.81 Mn |
| Jun 30, 2024 | 148.92 Mn |
| Mar 31, 2024 | 166.11 Mn |
| Dec 31, 2023 | 191.88 Mn |
| Sep 30, 2023 | 216.74 Mn |
| Jun 30, 2023 | 237.82 Mn |
| Mar 31, 2023 | 269.38 Mn |
| Dec 31, 2022 | 300.84 Mn |
| Sep 30, 2022 | 321.33 Mn |
| Jun 30, 2022 | 338.02 Mn |
| Mar 31, 2022 | 358.58 Mn |
| Dec 31, 2021 | 384.38 Mn |
| Sep 30, 2021 | 399.43 Mn |
| Jun 30, 2021 | 417.85 Mn |
| Mar 31, 2021 | 436.03 Mn |
| Dec 31, 2020 | 452.00 Mn |
| Sep 30, 2020 | 455.58 Mn |
| Jun 30, 2020 | 480.56 Mn |
| Mar 31, 2020 | 485.99 Mn |
| Dec 31, 2019 | 482.29 Mn |
| Sep 30, 2019 | 462.49 Mn |
| Jun 30, 2019 | 448.10 Mn |
| Mar 31, 2019 | 436.21 Mn |
| Dec 31, 2018 | 426.84 Mn |
| Sep 30, 2018 | 393.68 Mn |
| Jun 30, 2018 | 360.90 Mn |
| Mar 31, 2018 | 333.40 Mn |
| Dec 31, 2017 | 317.58 Mn |
| Sep 30, 2017 | 301.68 Mn |
| Jun 30, 2017 | 260.87 Mn |
| Mar 31, 2017 | 266.01 Mn |
| Dec 31, 2016 | 268.17 Mn |
| Sep 30, 2016 | 269.94 Mn |
| Jun 30, 2016 | 269.01 Mn |
| Mar 31, 2016 | 266.42 Mn |
| Dec 31, 2015 | 264.28 Mn |
| Sep 30, 2015 | 236.16 Mn |
| Jun 30, 2015 | 228.28 Mn |
| Mar 31, 2015 | 224.22 Mn |
| Dec 31, 2014 | 193.71 Mn |
| Sep 30, 2014 | 148.65 Mn |
| Jun 30, 2014 | 152.95 Mn |
| Mar 31, 2014 | 101.72 Mn |
| Dec 31, 2013 | 105.58 Mn |
| Sep 30, 2013 | 110.47 Mn |
| Jun 30, 2013 | 114.41 Mn |
| Mar 31, 2013 | 118.38 Mn |
| Sep 30, 2012 | -115.35 Mn |